Development of universal antibody therapy for Ebola hemorrhagic fever

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K14851
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Veterinary medical science
• Research Institution: Hokkaido University
• Principal Investigator: Takada Ayato 北海道大学, 人獣共通感染症リサーチセンター, 教授 (10292062)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 人獣共通感染症 / エボラウイルス / フィロウイルス / 抗体 / 治療法

Outline of Final Research Achievements

Ebolaviruses cause severe hemorrhagic fever (Ebola hemorrhagic fever) in humans and nonhuman primates. Five phylogenetically distinct species are currently known in the genus Ebolavirus and the antigenicity among these ebolavirus species is also largely different. This study attempted to establish procedures to induce neutralizing antibodies cross-reactive to all known ebolavirus species. Our data suggest the possibility that cross-reactive neutralizing antibodies can be induced more efficiently in mice immunized with virus-like particles using an immunosuppressive agent (rapamycin) or mice infected with replication competent vesicular stomatitis virus pseudotyped with ebolavirus glycoprotein than in mice immunized with virus-like particles using a standard adjuvant.

Free Research Field

ウイルス学